Robert Ross
President chez SURFACE ONCOLOGY, INC.
Fortune : - $ au 30/04/2024
Postes actifs de Robert Ross
Sociétés | Poste | Début | Fin |
---|---|---|---|
SURFACE ONCOLOGY, INC. | President | - | - |
Directeur/Membre du Conseil | 01/04/2021 | - | |
Directeur Général | 01/04/2021 | - | |
Directeur Technique/Scientifique/R&D | 01/10/2016 | 01/04/2021 | |
XILIO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 16/06/2022 | - |
Independent Dir/Board Member | 16/06/2022 | - | |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 03/09/2020 | - |
Historique de carrière de Robert Ross
Anciens postes connus de Robert Ross
Sociétés | Poste | Début | Fin |
---|---|---|---|
BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/10/2012 | 01/10/2016 |
Formation de Robert Ross
Stanford University | Undergraduate Degree |
Harvard Medical School | Graduate Degree |
Columbia University College of Physicians & Surgeons | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Opérationnelle
Director/Board Member | 3 |
Graduate Degree | 2 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
XILIO THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Robert Ross
- Expérience